PH12017501933A1 - Bromodomain inhibitor - Google Patents
Bromodomain inhibitorInfo
- Publication number
- PH12017501933A1 PH12017501933A1 PH12017501933A PH12017501933A PH12017501933A1 PH 12017501933 A1 PH12017501933 A1 PH 12017501933A1 PH 12017501933 A PH12017501933 A PH 12017501933A PH 12017501933 A PH12017501933 A PH 12017501933A PH 12017501933 A1 PH12017501933 A1 PH 12017501933A1
- Authority
- PH
- Philippines
- Prior art keywords
- methylisoquinolin
- methylsulfonylphenyl
- cyclopropylmethoxy
- bromodomain inhibitor
- pharmaceutical compositions
- Prior art date
Links
- 229940125763 bromodomain inhibitor Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- UWZAJPITKGWMFJ-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Chemical compound Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O UWZAJPITKGWMFJ-UHFFFAOYSA-N 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 crystalline forms Chemical compound 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000010922 spray-dried dispersion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 | |
| PCT/US2016/029029 WO2016172618A1 (en) | 2015-04-22 | 2016-04-22 | Bromodomain inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12017501933A1 true PH12017501933A1 (en) | 2018-03-19 |
Family
ID=57143581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12017501933A PH12017501933A1 (en) | 2015-04-22 | 2017-10-23 | Bromodomain inhibitor |
Country Status (22)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| JP7129973B2 (ja) * | 2016-10-20 | 2022-09-02 | セルジーン クオンティセル リサーチ，インク． | ブロモドメイン阻害剤 |
| KR102528406B1 (ko) | 2016-10-27 | 2023-05-03 | 셀젠 콴티셀 리서치, 인크. | 브로모도메인 및 엑스트라-말단 단백질 억제제 병용 치료요법 |
| KR20210058817A (ko) * | 2018-07-23 | 2021-05-24 | 셀젠 콴티셀 리서치, 인크. | 브로모도메인 억제제의 제조 방법 |
| CN117136057A (zh) * | 2021-02-22 | 2023-11-28 | 赛尔基因昆蒂赛尔研究公司 | 用于治疗前列腺癌的溴结构域(bet)抑制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| HUE060767T2 (hu) * | 2013-10-18 | 2023-04-28 | Celgene Quanticel Res Inc | Brómdomén inhibitorok |
| JP7129973B2 (ja) * | 2016-10-20 | 2022-09-02 | セルジーン クオンティセル リサーチ，インク． | ブロモドメイン阻害剤 |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2983446C (en) | 2024-04-09 |
| KR20170139119A (ko) | 2017-12-18 |
| NZ736630A (en) | 2024-03-22 |
| AR104340A1 (es) | 2017-07-12 |
| PE20180036A1 (es) | 2018-01-09 |
| MX2017013501A (es) | 2018-02-09 |
| JP2018513863A (ja) | 2018-05-31 |
| IL255120A0 (en) | 2017-12-31 |
| SG11201708627TA (en) | 2017-11-29 |
| HK1243948A1 (zh) | 2018-07-27 |
| CA2983446A1 (en) | 2016-10-27 |
| MX390077B (es) | 2025-03-20 |
| CN107613981A (zh) | 2018-01-19 |
| CO2017011482A2 (es) | 2018-01-31 |
| IL255120B (en) | 2021-03-25 |
| WO2016172618A1 (en) | 2016-10-27 |
| EP3285770A4 (en) | 2018-10-31 |
| TW201642860A (zh) | 2016-12-16 |
| ZA201707186B (en) | 2019-01-30 |
| AU2016252992A1 (en) | 2017-11-09 |
| MX377159B (es) | 2025-03-07 |
| US20160310423A1 (en) | 2016-10-27 |
| EP3285770A1 (en) | 2018-02-28 |
| MX2020010899A (es) | 2022-02-15 |
| EA201792317A1 (ru) | 2018-03-30 |
| CL2017002679A1 (es) | 2018-05-25 |
| BR112017022691A2 (pt) | 2018-07-17 |
| ECSP17071545A (es) | 2017-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501933A1 (en) | Bromodomain inhibitor | |
| MX2022009998A (es) | Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida. | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| WO2019191092A8 (en) | Compounds for treating huntington's disease | |
| CR20200545A (es) | Inhibidores magl | |
| MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| MX389597B (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| WO2018226622A8 (en) | Compounds for treating huntington's disease | |
| WO2015168466A8 (en) | Inhibitors of lysine specific demethylase-1 | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| TN2016000270A1 (en) | Heteroaryls and uses thereof. | |
| ZA202004023B (en) | 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| EP4327887A3 (en) | Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease | |
| WO2019073331A3 (en) | Pharmaceutical compositions of apremilast | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| MX2019004375A (es) | Inhibidores de bromodominios. | |
| EP3820477A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| WO2018211324A8 (en) | Prodrugs for the treatment of disease | |
| MX2019001771A (es) | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. | |
| MX2019004187A (es) | Inhibidores de bromodominios. |